The Group of Biomedical Research in Digestive Tract Tumors is directed by Dr. Diego Arango, who graduated in Biological Sciences in 1994 at Universidad Autónoma de Madrid (Spain) and obtained his PhD in 1998 at the University College Dublin (Ireland), where he became familiar with the anatomy and physiology of the intestine, and studied different ways of manipulating the cell cycle of intestinal stem cells in an attempt to minimize the side effects of radiotherapy in the abdominal and pelvic region.
From 1999 to 2003, Dr. Arango was a Postdoctoral Fellow and an Instructor of Medicine at the Albert Einstein Cancer Center in New York (USA), where he gained extensive knowledge on the different genomic approaches to understand the molecular differences between normal and tumor tissue as well as between tumors from patients with good and bad prognosis or response to treatment.
Dr. Arango moved in 2003 to the Center of Excellence in Disease Genetics at Biomedicum Helsinki (Finland) as a Visiting Scientist, where he began different lines of independent research aimed at the molecular classification of colorectal cancer using high throughput genome-wide transcriptomic analysis. In 2005, Dr. Arango became the Leader of the Group Biomedical Research in Digestive Tumors at Vall d’Hebron Hospital Research Institute in Barcelona and is now the coordinator of the Oncology Area at Vall d’Hebron Research Institute (since January 2016).
Dr. Arango has over 60 publications in leading peer-reviewed journals and several patents for biomarkers of prognosis and response to treatment for cancer (EP15382184, PCT/ES2006/000704, PCT/EP2007/056222 and PCT/ES2010/070576). He is also a regular reviewer for over 40 leading journals in his field (including Nature Communications, Gastroenterology, Cancer Research, Oncogene, International Journal of Cancer, Clinical Cancer Research, Molecular Cancer Research, The journal of Pathology, Gut and Journal of Cellular Physiology) and participates in the evaluation of projects submitted for funding by his peers to national and international funding agencies (European Union FP7 and H2020; Cancer Research UK; National Cancer Institute, France; Irish Health Research Board, Ireland; South African Research Council, South Africa; and Spanish National Evaluation Agency among others).